Case Study – Evidence For The Utility Of AI In Ki-67 Quantification In Solid Tumors

Although it is an important biomarker in oncology (mostly in breast and prostate), Ki-67 immunohistochemistry (IHC) analysis has yet to be standardized. Working groups have provided guidelines for Ki-67 scoring in different cancer types to limit pathologist’s variability.

Digital analysis solutions to assist scoring with image analysis or artificial intelligence (AI) have recently emerged in the evaluation of Ki-67 as rapid and robust solutions. In this context, we compared the results of Ki-67 scoring performed with Aiforia Platform ® (AI platform) and Halo ® (image analysis supervised software) against three independent pathologists on various solid tumors.

Discover more about this in the case study.